The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Items 301–400 of 1,002
Haddox, C. L., Han, G., Anijar, L., Binitie, O. T., Letson, G. D., Bui, M. M., & Reed, D. R. (2014) · Sarcoma · doi:10.1155/2014/402509 · Cited by 53
Ray, S., Mishra, A., Mandal, T. K., Sa, B., & Chakraborty, J. (2015) · RSC Advances · doi:10.1039/c5ra15859a · Cited by 53
Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling
Cao, Y., Yu, L., Dai, G., Zhang, S., Zhang, Z., Gao, T., & Guo, W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.016 · Cited by 53
Chang, J., Li, Y., Wang, X., Hu, S., Wang, H., Shi, Q. W., Wang, Y., & Yang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-07194-9 · Cited by 53
Williams, R. F., Fernández‐Pineda, I., & Gosain, A. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.05.012 · Cited by 53
Bishop, M. W., Chang, Y., Krailo, M. D., Meyers, P. A., Provisor, A. J., Schwartz, C. L., Marina, N. M., Teot, L. A., Gebhardt, M. C., Gorlick, R., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26034 · Cited by 52
Identification of Prognostic and Predictive Osteosarcoma Biomarkers
Zamborský, R., Kokavec, M., Harsányi, Š., & Danišovič, Ľ. (2019) · Medical Sciences · doi:10.3390/medsci7020028 · Cited by 53
Differential expression and bioinformatics analysis of circRNA in osteosarcoma
Xi, Y., Fowdur, M., Liu, Y., Wu, H., He, M., & Zhao, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181514 · Cited by 52
Imaging of skull vault tumors in adults
Pons‐Escoda, A., Naval‐Baudin, P., Paloma Mora, M., Cos, M., Gañán, J. H., Narváez, J. A., Aguilera, C., & Majós, C. (2020) · Insights into Imaging · doi:10.1186/s13244-019-0820-9 · Cited by 52
Wang, Y., & Kong, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26230 · Cited by 51
RetractedA comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma
Yang, H., Zhao, L., Zhang, Y., & Li, F. (2021) · Cancer Medicine · doi:10.1002/cam4.4117 · Cited by 52
A systems biology approach reveals common metastatic pathways in osteosarcoma
Flores, R. J., Li, Y., Yu, A. K.-T., Shen, J. J., Rao, P. H., Lau, S. S., Vannucci, M., Lau, C. C., & Man, T. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-50 · Cited by 51
Hingorani, P., Janeway, K. A., Crompton, B. D., Kadoch, C., Mackall, C. L., Khan, J. I., Shern, J. F., Schiffman, J. D., Mirabello, L. J., Savage, S. A., et al. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.004 · Cited by 51
Self-citationLu, K., Chen, P., Hsieh, Y., Lin, C.-Y., Cheng, F.-Y., Chiu, P.-C., Chu, S., & Hsieh, Y. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.09.006 · Cited by 51
Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma
Nakka, M., Allen‐Rhoades, W. A., Li, Y., Kelly, A. J., Shen, J. J., Taylor, A. M., Barkauskas, D. A., Yustein, J. T., Andrulis, I. L., Wunder, J. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18236 · Cited by 52
Zhang, Z., Tang, C. Y., Dong, Y., Zhang, J., Yuan, T., Tao, S., & Li, X. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.22249 · Cited by 51
Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma
Lu, K., Lin, R.-C., Yang, J., Yang, W., Reiter, R. J., & Yang, S. (2019) · Cells · doi:10.3390/cells8121618 · Cited by 51
A review of imaging of surface sarcomas of bone
Harper, K., Sathiadoss, P., Saifuddin, A., & Sheikh, A. M. (2020) · Skeletal Radiology · doi:10.1007/s00256-020-03546-1 · Cited by 53
Li, M., Chen, H., Zhao, Y., Gao, S., & Cheng, C. (2016) · DNA and Cell Biology · doi:10.1089/dna.2015.3171 · Cited by 53
RetractedEGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
Linder, M., Glitzner, E., Srivatsa, S., Bakiri, L., Matsuoka, K., Shahrouzi, P., Dumanic, M., Novoszel, P., Mohr, T. T., Langer, O., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809408 · Cited by 51
Nguyen, J. C., Baghdadi, S., Pogoriler, J. E., Guariento, A., Rajapakse, C. S., & Arkader, A. (2022) · Radiographics · doi:10.1148/rg.210171 · Cited by 50
Oral and maxillofacial osteosarcoma in dogs: a review
Farcas, N., Arzi, B., & Verstraete, F. J. Μ. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00352.x · Cited by 50
Bao, M., Cao, Z., Yu, D., Fu, S., Zhang, G., Yang, P., Pan, Y., Yang, B., Han, H., & Zhou, Q. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.10.015 · Cited by 50
Berberine induces apoptosis and DNA damage in MG-63 human osteosarcoma cells
Zhu, Y., Ma, N., Li, H., Tian, L., Ba, Y., & Hao, B. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2405 · Cited by 50
Jiang, R., Zhang, C., Liu, G., Gu, R., & Wu, H. (2017) · PubMed Central · Cited by 50
Villanueva, F., Araya, H., Briceño, P., Varela, N., Stevenson, A., Jerez, S., Tempio, F., Chnaiderman, J., Perez, C., Milena Villarroel, C., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28046 · Cited by 50
Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway
YU, X., Zhou, X., Fu, C., WANG, Q., Nie, T., ZOU, F., Guo, R., Liu, H., Zhang, B., & Dai, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4124 · Cited by 49
Cheng, H.-L., Lin, C., Yang, J., Hsieh, M., Yang, S., & Lu, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7138 · Cited by 49
Li, K., Chen, Q., Wang, D., Duan, Q., Tian, S., He, J., Ou, Y., & Bai, D. (2016) · Cancer Medicine · doi:10.1002/cam4.895 · Cited by 49
Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2
Ruan, J., Zheng, L., Hu, N., Guan, G., Chen, J., Zhou, X., & Li, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.03.036 · Cited by 49
Current questions in bone sarcomas
Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49
Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma
Yang, Q., Chen, T., Yao, Z., & Zhang, X. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-1789-z · Cited by 49
Incidence and mortality of bone cancer among children, adolescents and young adults of Brazil
Balmant, N. V., Reis, R. D. S., Santos, M. D. O., Maschietto, M. C., & de Camargo, B. (2019) · Clinics · doi:10.6061/clinics/2019/e858 · Cited by 48
Ailanthone: A novel potential drug for treating human cancer (Review)
Ding, H., Yu, X., Chen, H., Gao, K., Lao, X., Jia, Y., & Yan, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11710 · Cited by 48
The Osteoclast Traces the Route to Bone Tumors and Metastases
Russo, S., di Carlo, F. S., & Gianfrancesco, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.886305 · Cited by 50
Oncogenic roles of astrocyte elevated gene-1 (AEG-1) in osteosarcoma progression and prognosis
Wang, F., Ke, Z., Sun, S., Chen, W., Yang, S., Li, S., Mao, X., & Wang, L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.16301 · Cited by 48
Pu, Y., Yi, Q., Zhao, F., Wang, H., Cai, W., & Cai, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0340-3 · Cited by 48
RetractedPARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
Lei, Z., Duan, H., Zhao, T., Zhang, Y., Li, G., Meng, J., Zhang, S., & Yan, W. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0401-8 · Cited by 48
Wang, S., Hu, H., Zhong, B., Shi, D., Qing, X., Cheng, C., Deng, X., Zhang, Z., & Shao, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2612 · Cited by 48
Targeting anti-cancer agents to bone using bisphosphonates
Xing, L., Ebetino, F. H., Boeckman, R. K., Srinivasan, V., Tao, J., Sawyer, T. K., Li, J., Yao, Z., & Boyce, B. F. (2020) · Bone · doi:10.1016/j.bone.2020.115492 · Cited by 48
The epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002
Eyre, R., Feltbower, R. G., James, P. W., Blakey, K., Mubwandarikwa, E., Forman, D., McKinney, P. A., Pearce, M. S., & McNally, R. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-357 · Cited by 48
Zou, Q., Xiao, X., Liang, Y. J., Peng, L., Guo, Z., Li, W., & Yu, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.027 · Cited by 47
Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis
Hou, X.-K., & Mao, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.016 · Cited by 47
Zhang, A., He, S.-H., Sun, X., Ding, L., Bao, X., & Wang, N. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-15 · Cited by 47
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 47
Jiramongkolchai, P., Owens, P., & Hong, C. C. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160069 · Cited by 47
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Murahari, S., Jalkanen, A., Kulp, S. K., Chen, C., Modiano, J. F., London, C. A., & Kisseberth, W. C. (2017) · BMC Cancer · doi:10.1186/s12885-017-3046-6 · Cited by 47
Exosomes in Bone Sarcomas: Key Players in Metastasis
Chicón‐Bosch, M., & Tirado, Ò. M. (2020) · Cells · doi:10.3390/cells9010241 · Cited by 50
Design strategies and evolving role of biomaterial assisted treatment of osteosarcoma
Quadros, M., Momin, M. M., & Verma, G. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.111875 · Cited by 47
Blakey, K., Feltbower, R. G., Parslow, R. C., James, P. W., Gómez‐Pozo, B., Stiller, C. A., Vincent, T. J., Norman, P. D., McKinney, P. A., Murphy, M. F. G., et al. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt259 · Cited by 47
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
Yin, M., Wang, H., Yang, X., Xu, C., Wang, T., Yan, Y., Fan, Z., Ma, J., Ye, J., & Mo, W. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3429-4 · Cited by 46
Adverse impact of regional lymph node involvement in osteosarcoma
Thampi, S., Matthay, K. K., Goldsby, R. E., & DuBois, S. G. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.023 · Cited by 46
TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma
Liang, J., Xing, D., Li, Z., Shen, J., Zhao, H., & Li, S. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5183 · Cited by 46
Song, K., Song, J., Chen, F., Lin, K., Ma, X., & Jiang, J. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.09.012 · Cited by 46
18F-FDG PET/CT in the Management of Osteosarcoma
Oh, C., Bishop, M. W., Cho, S. Y., Im, H., & Shulkin, B. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265592 · Cited by 45
Jin, H., & Wang, W. (2015) · PubMed Central · Cited by 45
Sun, L., Li, Y., Zhang, J., Li, H., Li, B., & Ye, Z. (2014) · Journal of Orthopaedic Research® · doi:10.1002/jor.22734 · Cited by 45
Wang, K., Zhuang, Y., Liu, C., & Li, Y. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.07.003 · Cited by 45
Genetically engineered mouse models and human osteosarcoma
Ng, A. J., Mutsaers, A. J., Baker, E. K., & Walkley, C. R. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-19 · Cited by 45
Liu, Y., Li, Y., Liu, J., WU, Y., & Zhu, Q. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3147 · Cited by 45
RetractedRadiologic Assessment of Osteosarcoma Lung Metastases: State of the Art and Recent Advances
Chiesa, A. M., Spinnato, P., Miceli, M., & Facchini, G. (2021) · Cells · doi:10.3390/cells10030553 · Cited by 44
Molecular Mechanism of Ferroptosis in Orthopedic Diseases
Gao, L., Hua, W., Tian, L., Zhou, X., Wang, D., Yang, Y., & Ni, G. (2022) · Cells · doi:10.3390/cells11192979 · Cited by 44
Different Subtypes of Osteosarcoma: Histopathological Patterns and Clinical Behaviour
Rothzerg, E., Xu, J., & Wood, D. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4020011 · Cited by 44
Role of miR‑181a‑5p in cancer (Review)
Li, J., Shen, J., Zhao, Y., Du, F., Li, M., Xu, X., Chen, Y., Wang, S., Xiao, Z., & Wu, Z. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5556 · Cited by 47
Deng, C., Xu, Y., Chen, H., Zhu, X., Huang, L., Chen, Z., Xu, H., Song, G., Lu, J., Huang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113751 · Cited by 45
Zorrón, M., Cabrera, A. L., Sharma, R., Radhakrishnan, J., Abbaszadeh, S., Shahbazi, M., Tafreshi, O. A., Karamikamkar, S., & Maleki, H. H. (2024) · Advanced Science · doi:10.1002/advs.202403204 · Cited by 51
Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy
Ballatori, S. E., & Hinds, P. W. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.1 · Cited by 45
Zhao, Y., Tu, M., Wang, W.-P., Qiu, J.-X., Yu, A.-X., & Yu, A. (2016) · Scientific Reports · doi:10.1038/srep26611 · Cited by 44
Xie, C., Wu, B., Chen, B., Shi, Q., Guo, J., Fan, Z., & Huang, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105418 · Cited by 44
Telangiectatic osteosarcoma: a review of 87 cases
Angelini, A., Mavrogenis, A. F., Trovarelli, G., Ferrari, S., Picci, P., & Ruggieri, P. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2210-8 · Cited by 44
Meier, D., Botter, S. M., Campanile, C., Robl, B., Gräfe, S., Pellegrini, G., Born, W., & Fuchs, B. (2016) · International Journal of Cancer · doi:10.1002/ijc.30572 · Cited by 44
Yang, X., Wang, L., Wang, Q., Li, L., Fu, Y., & Sun, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.170 · Cited by 44
Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy
Wang, F., Pang, J., Huang, L., Wang, R., Li, D., Sun, K., Wang, L., & Zhang, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s147747 · Cited by 44
Zocchi, L., Wu, S., Wu, J., Hayama, K. L., & Benavente, C. A. (2018) · Oncotarget · doi:10.18632/oncotarget.25239 · Cited by 44
Jin, W., Zhou, L., Yan, B., Li, Y., Liu, F., Tong, P., Yu, W., Dong, X., Xie, L., Zhang, J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13742 · Cited by 44
miR-328-3p mediates the anti-tumor effect in osteosarcoma via directly targeting MMP-16
Shi, J., An, G., Guan, Y., Wei, T., Peng, Z., Liang, M., & Wang, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0829-7 · Cited by 44
What’s new in bone forming tumours of the skeleton?
Franceschini, N., Lam, S. W., Cleton-Jansen, A., & Bovée, J. V. M. G. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02683-w · Cited by 44
Naringenin Induces ROS-Mediated ER Stress, Autophagy, and Apoptosis in Human Osteosarcoma Cell Lines
Lee, C., Huang, C. C., Chi, M., Lee, K., Peng, K., Fang, M.-L., Chiang, Y., & Liu, J. (2022) · Molecules · doi:10.3390/molecules27020373 · Cited by 44
Martins‐Neves, S. R., Sampaio-Ribeiro, G., & Gomes, C. M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098401 · Cited by 44
Nandra, R. S., Hwang, N., Matharu, G., Reddy, K., & Grimer, R. J. (2015) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588415x14181254790284 · Cited by 43
Global incidence of primary malignant bone tumors
Kumar, N., & Gupta, B. (2016) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000000405 · Cited by 43
Pereira, H. M., Duarte, M. E. L., Damasceno, I. R., Santos, L. A. D. O. M., & Nogueira‐Barbosa, M. H. (2021) · British Journal of Radiology · doi:10.1259/bjr.20201391 · Cited by 43
Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
Chen, J., Qian, C., Ren, P., Han, Y., Kong, X., Huang, C., Luo, H., & Chen, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679610 · Cited by 43
Ling, Z., Yang, C. H., Tan, J., Dou, C., & Chen, Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03966-9 · Cited by 43
Shi, D., Mu, S., Pu, F., Liu, J., Zhong, B., Hu, B., Ni, N., Wang, H., Luu, H. H., Haydon, R. C., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13160 · Cited by 43
Phytocompounds and Nanoformulations for Anticancer Therapy: A Review
Bozzuto, G., Calcabrini, A., Colone, M., Condello, M., Dupuis, M. L., Pellegrini, E., & Stringaro, A. (2024) · Molecules · doi:10.3390/molecules29163784 · Cited by 42
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 42
Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy
Robl, B., Pauli, C., Botter, S. M., Bode‐Lesniewska, B., & Fuchs, B. (2015) · BMC Cancer · doi:10.1186/s12885-015-1397-4 · Cited by 42
Telomere length and variation in telomere biology genes in individuals with osteosarcoma.
Mirabello, L., Richards, E. G., Duong, L. M., Yu, K. F., Wang, Z., Cawthon, R., Berndt, S. I., Burdett, L. A., Chowdhury, S., Teshome, K., et al. (2011) · PubMed Central · Cited by 42
Self-citationNamløs, H. M., Kresse, S. H., Müller, C. R., Henriksen, J. M., Holdhus, R., Sæter, G., Bruland, Ø. S., Bjerkehagen, B., Steen, V. M., & Myklebost, O. (2012) · Sarcoma · doi:10.1155/2012/639038 · Cited by 42
MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA
Shi, Z., Chu, X.-R., Wu, Y., Wu, J.-H., Lu, C., Lü, R.-X., Ding, M., & Mao, N. (2015) · Tumor Biology · doi:10.1007/s13277-015-3614-9 · Cited by 42
DI, W., Khan, M. N., Rasul, A., Sun, M., Sui, Y., Zhong, L., Yang, L., Zhu, Q., Feng, L., & Ma, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3368 · Cited by 42
Hingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., Teicher, B., Erickson, S., Gatto, G., Smith, M. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0406 · Cited by 41
Dailey, D. D., Anfinsen, K. P., Pfaff, L. E., Ehrhart, E. J., Charles, J. B., Bønsdorff, T. B., Thamm, D. H., Powers, B. E., Jónasdóttir, T. J., & Duval, D. L. (2013) · BMC Veterinary Research · doi:10.1186/1746-6148-9-130 · Cited by 41
Fiore, R. D., Drago‐Ferrante, R., Pentimalli, F., Marzo, D. D., Forte, I. M., Carlisi, D., BLASIO, A. D., Tesoriere, G., Giordano, A., & Vento, R. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25291 · Cited by 41
Wen, X., Wang, N., Zhang, F., & Dong, C. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4857 · Cited by 41
Zhang, F., & Peng, H. (2017) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-017-0599-7 · Cited by 41
Li, Q.-C., Xu, H., Wang, X., Wang, T., & Wu, J. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170452 · Cited by 41
Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review
Jauregui, J. J., Nadarajah, V., Munn, J. S., Pivec, R., Kapadia, B. H., Lerman, D. M., & Maheshwari, A. V. (2018) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-018-0725-y · Cited by 42
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
